ISIN.net news update courtesy of Business Wire, the clinical-stage French nanomedicine company, Nanobiotix (Euronext: NANO) is a pioneer in working on the local treatment of cancer.
Companies that wish to provide public notice of updates, changes or additions to securities using International Securities Identification Number (ISIN) issued by the company may do so courtesy of ISIN.net corporate services.
PARIS–(BUSINESS WIRE)–NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage French nanomedicine company (the “Company”) working on the local treatment of cancer, and listed on Euronext, Paris, announced the completion of a private placement on November 24, 2014.
The private placement was carried out in accordance with applicable French and U.S. private placement exemptions, and has been made with Capital Ventures International (“CVI”), a U.S. investor, and includes the following securities and terms:
The private placement was completed on November 24, 2014. Piper Jaffray & Co. and its affiliates served as sole lead placement agent and Trout Capital served as co-placement agent for the private placement.
The purpose of the offering is to provide Nanobiotix with funding to assist in the development of NBTRXR3, its main product, including for the purposes of (i) continuing a soft tissue sarcoma registration clinical trial being conducted by the Company; (ii) expanding its clinical development program; (iii) investigating new clinical indications in the United States and Europe; and (iv) extending capabilities of the new subsidiary in the United States